Shopping Cart
- Remove All
- Your shopping cart is currently empty
EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/T790M/C797S. It lacks significant inhibitory effects on EGFR WT. Demonstrating anti-proliferative properties, EGFR-IN-82 also inhibits tumor growth in nude mice, rendering it applicable in non-small cell lung cancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/T790M/C797S. It lacks significant inhibitory effects on EGFR WT. Demonstrating anti-proliferative properties, EGFR-IN-82 also inhibits tumor growth in nude mice, rendering it applicable in non-small cell lung cancer research [1]. |
In vitro | EGFR-IN-82 (compound 8a), following a 72 hour exposure, significantly inhibited the growth of Ba/F3-EGFR Del19/T790M/C797S cells, with an IC50 value of 12.7 nM, yet exhibited no notable effect on the proliferation of A431 cells [1]. |
In vivo | EGFR-IN-82 (compound 8a) exhibits superior pharmacokinetic properties to Brigatinib [1]. When administered orally at 15-30 mg/kg for 14-21 days, EGFR-IN-82 moderately inhibits tumor growth in a PC9-EGFR Del19/T790M/C797S xenograft mouse model and significantly inhibits growth in a Ba/F3-EGFR Del19/T790M/C797S xenograft model [1]. Pharmacokinetic analysis in Balb/C mice showed the following parameters [1]: Route: p.o.; Dose: 5 mg/kg; C_max: 1574 ng/mL; AUC_0-t: 15375 ng/mL*h; AUC_0-∞: 15632 ng/mL*h; t_1/2: 3.5 h; MRT: 6 h. |
Molecular Weight | 694.6 |
Formula | C32H41BrN9O2P |
Cas No. | 2568086-81-5 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.